The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis

Biochemical Pharmacology

Volumn 66, Issue 8, 2003, Pages 1537-1545

  Zhang, Xu Dong ^a   Gillespie, Susan K ^a   Borrow, Jodie M ^a   Hersey, Peter ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

c IAP; Cellular inhibitor of apoptosis; HDAC; Histone deacetylases; IAP; ICAD; Inhibitor of apoptosis proteins; Inhibitor of caspase activated DNase; PARP; SBHA; Suberic bishydroxamate; TNF related apoptosis inducing ligand; TRAIL; X linked IAP; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE; CASPASE 3; CASPASE 8; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; SUBERIC BISHYDROXAMATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; APOPTOSIS REGULATORY PROTEIN; DICARBOXYLIC ACID; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MEMBRANE PROTEIN; OCTANOIC ACID DERIVATIVE; SUBERIC ACID; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL GROWTH; CHEMOSENSITIVITY; CONFERENCE PAPER; CYTOTOXICITY; DRUG SENSITIZATION; GENETIC TRANSCRIPTION; GROWTH DISORDER; MELANOCYTE; MELANOMA; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; REVIEW;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CAPRYLATES; DICARBOXYLIC ACIDS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MELANOMA; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0642345200     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00509-4     Document Type: Conference Paper

References (81)

1. Csordas A. On the biological role of histone acetylation. Biochem. J. 265:1990;23-38.
2. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080.
3. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
4. Hassig C.A., Schreiber S.L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1:1997;300-308.
5. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9:1999;40-48.
6. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
7. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 18:1999;2449-2458.
8. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D., Ponder B.A., Kouzarides T., Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24:2000;300-303.
9. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H. Jr., Evan R.M. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature. 391:1998;811-814.
10. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp. 5:1996;245-253.
11. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishis O. A synthetic inhibitor of histone deacetylase inhibitor, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc. Natl. Acad. Sci. U.S.A. 95:1999;4592-4597.
12. Archer S.Y., Meng S., Shel A., Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6791-6796.
13. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., Xu H., Cohen D.J. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:1999;34940-34947.
14. Janson W., Brandner G., Siegel J. Butyrate modulates DNA damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene. 15:1997;1395-1406.
15. Parson P.G., Hansen C., Fairlie D.P., West M.L., Danoy P.A.C., Sturm R.A., Dunn I.S., Pedley J., Ablett E.M. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. 53:1997;1719-1724.
16. Saunders N., Dicker A., Popa C., Jones S., Dahler A. Histone deacetylase inhibitors as potential antiskin cancer agents. Cancer Res. 59:1999;399-404.
17. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61:2001;8492-8497.
18. Bernhard D., Ausserlechner M.J., Tonko M., Loffler M., Hartmann B.L., Csordas A., Kofler R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 13:1999;1991-2001.
19. WAF1/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60:2001;828-837.
20. Medina V., Edmonds B., Young G.P., James R., Appleton S., Zalewski P.D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57:1997;3697-3707.
21. Coffey D.C., Kutko M.C., Glick R.D., Butler L.M., Heller G., Rifkind R.A., Marks P.A., Richon V.M., Quaglia M.P.La. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, along and synergistically with all-trans retinoic acid. Cancer Res. 61:2001;3591-3594.
22. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., Brooks R., Piekarz R.L., Tucker E., Figg W.D., Chan K.K., Goldspiel B., Fojo A.T., Balcerzak S.P., Bates S.E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Can. Res. 8:2002;718-728.
23. Mandel M., Kumar R. Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ. 7:1996;311-318.
24. Hague A., Diaz G.D., Hicks D.J., Krajewski S., Reed J.C., Paraskeva C. Bcl-2 and bak may play a pivotal role in sodium bytyrate-induced apoptosis in colonic epithelial cells however, overexpression of Bcl-2 does not protect against bak-mediated apoptosis. Int. J. Cancer. 72:1997;898-905.
25. Cao X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor down-regulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol. 25:2001;562-568.
26. Goh M., Chen F., Paulsen M.T., Yeager A.M., Dyer E.S., Ljungman M. Phenylbutyrate ttenuates the expression of Bcl-XL, DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasm. 3:2001;331-338.
27. Bernhard D., Skvortsov S., Tinhofer I., Hubl H., Grell R., Csordas A., Kofler R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 8:2001;1014-1021.
28. Bonnotte B., Favre N., Reveneau S., Micheau O., Drion N., Garrido C., Fontana A., Chauffert B., Solary E., Martin F. Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate. Cell Growth Differ. 5:1998;480-487.
29. Herold K., Rothberg P. Evidence for a labile intermediate in the butyrate-induced reduction of the level of c-myc RNA in SW 837 rectal carcinoma cells. Oncogene. 4:1998;423-428.
30. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.-U., Yoon J.W., Hong S., Lee H.Y., Lee Y.-W., Lee H.-W., Han J.-W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277:2002;2073-2082.
31. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10833-10838.
32. Kim Y.B., Lee K.H., Sugita K., Yoshida M., Horinouchi S. Oxamflatinis a novel antitumour compound that inhibits mammalian histone deacetylase. Oncogene. 18:1999;2461-2470.
33. WAF1/CIP1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10014-10019.
34. Gray S.G., Yakolva T., Hartmann W., Tally M., Baklakin G., Ekstrom T.J. IBF-II enhance trichostatin A-induced TGFβ1 and p21 (Waf1, Cip 1, sdi 1) expression in Hep3B cells. Exp. Cell Res. 253:1999;618-628.
35. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.-P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
36. Pitti R.M., Marsters S.A., Rupper S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:1996;12687-12690.
37. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10:1998;559-563.
38. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59:1999;2747-2753.
39. Hersey P., Zhang X.D. How melanoma cells evade TRAIL-induced apoptosis. Nat. Rev. 1:2001;142-150.
40. Hersey P., Zhang X.D. Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol. 9999:2003;1-10.
41. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma. J. Immunol. 15:1998;2833-2840.
42. Hofmann K., Bucher P., Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem. Sci. 22:1997;155-156.
43. Zhang X.D., Zhang X.Y., Nguyen D.T., Gray C., Hersey P. Regulation of TRAIL-induced apoptosis of melanoma by release of Smac/DIABLO from mitochondria. Cancer Res. 61:2001;7339-7348.
44. Thomas W.D., Zhang X.D., Franco A.V., Nguyen T., Hersey P. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J. Immunol. 165:2000;5612-5620.
45. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 8:2001;705-711.
46. Puthalakath H., Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9:2002;505-512.
47. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7:2000;1166-1173.
48. Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts 2001;276:22491-9.
49. Zhang XD, Gillespie S, Borrow J, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces apoptosis by triggering changes in mitochondrial membrane permeability melanoma cells, submitted for publication.
50. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
51. Gross A., Jockel J., Wei M.C., Korsmeyer S.J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17:1998;3878-3885.
52. Nechushtan A., Smith C.L., Hsu Y.T., Youle R.J. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J. 18:1999;2330-2341.
53. Hsu Y.T., Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J. Biol. Chem. 273:1998;10777-10783.
54. Desagher S., Osen-Sand A., Nichols A., Eskes R., Montessuit S., Lauper S., Maundrell K., Antonsson B., Martinou J.C. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144:1999;891-901.
55. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer. 2:2002;764-776.
56. Soucie E.L., Annis M.G., Sedivy J., Filmus J., Leber B., Andrews D.W., Penn L.Z. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol. Cell Biol. 21:2001;4725-4736.
57. Strasser A., Puthalakath H., Bouillet P., Huang D.C., O'Connor L., O'Reilly L.A., Cullen L., Cory S., Adams J.M. The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann. N.Y. Acad. Sci. 917:2000;541-548.
58. Puthalakath H., Villunger A., O'Reilly L.A., Beaumont J.G., Coultas L., Cheney R.E., Huang D.C., Strasser A. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 293:2001;1829-1832.
59. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058.
60. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell. 7:2001;683-694.
61. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 8:2001;705-711.
62. Korsmeyer S.J., Gross A., Harada H., Zha J., Wang K., Yin X.M., Wei M., Zinkel S. Death and survival signals determine active/inactive conformations of pro-apoptotic BAX, BAD, and BID molecules. Cold Spring Harb. Symp. Quant. Biol. 64:1999;343-350.
63. Dijkers P.F., Medema R.H., Lammers J.W., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10:2000;1201-1204.
64. Dijkers P.F., Birkenkamp K.U., Lam E.W., Thomas N.S., Lammers J.W. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol. 156:2002;531-542.
65. Whitfield J., Neame S.J., Paquet L., Bernard O., Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron. 29:2001;629-643.
66. Kokontis J.M., Wagner A.J., O'Leary M., Liao S., Hay N. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene. 20:2001;659-668.
67. Mahyar-Roemer M., Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene. 20:2001;3387-3398.
68. WAF1/CIP1-induced apoptosis in human ovarian cancer cells. Biol. Chem. 277:2002;36329-36337.
69. Agrawal S., Agarwal M.L., Chatterjee-Kishore M., Stark G.R., Chisolm G.M. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol. Cell Biol. 22:2002;1981-1992.
70. Kim Y.B., Ki S.W., Yoshida M., Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot. 53:2000;1191-1200.
71. Hinnebusch B.F., Meng S., Wu J.T., Archer S.Y., Hodin R.A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 132:2002;1012-1017.
72. Zhang XD, Borrow J, Zhang XY, Nguyen T, Hersey P. Activation of Erk1/2 protects melanoma from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003, in press.
73. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., Cordon-Cardo C., Lowe S.W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409:2001;207-211.
74. Bird A.P., Wolffe A.P. Methylation-induced repression - belts, braces, and chromatin. Cell. 99:1999;451-454.
75. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., Schrump D.S. Modulation of p53, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. 94:2002;504-513.
76. Bonavida B., Ng C.P., Jazirehi A., Schiller G., Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to nontoxic cancer therapeutics (review). Int. J. Oncol. 15:1999;793-802.
77. El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8:2001;1066-1075.
78. Lacour S., Hammann A., Wotawa A., Corcos L., Solary E., Dimanche-Boitrel M.T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 61:2001;1645-1651.
79. Zisman A., Ng C.P., Pantuck A.J., Bonavida B., Belldegrun A.S. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J. Immunother. 24:2001;459-471.
80. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62:2002;5800-5806.
81. Nguyen T., Zhang X.D., Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin. Cancer Res. 7:2001;966s-973s.